# Keystone Heart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keystone-heart

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Website: www.keystoneheart.com
- Total disclosed funding: $14M
- Latest round: Series B (May 15, 2014)
- Investors on record: 2

## About

Keystone Heart Ltd. is a medical device company focused on developing innovative monitoring systems for cardiovascular health, enhancing patient outcomes through advanced telemetry and real-time data tracking solutions.Founded in 2004 in Israel, Keystone Heart Ltd. specializes in cardiovascular monitoring solutions. The company operates with a clear focus on developing advanced medical devices tailored for hospitals and healthcare professionals. In September 2018, Keystone Heart was acquired by Venus MedTech (HangZhou) Inc., as part of a broader strategy to enhance its product offerings. The company has raised a total of USD 14.00 mn, with the latest funding round being a Series B led by OrbiMed Advisors, including investors such as Caesarea Medical Electronics Ltd. and OrbiMed Advisors. This round marked the culmination of their fundraising efforts to date.Keystone Heart Ltd. specializes in innovative medical devices aimed at addressing cardiovascular conditions. Their flagship product is a proprietary heart monitoring system that combines advanced telemetry with user-friendly interfaces for real-time patient data tracking. This system is designed to enhance patient outcomes by enabling healthcare providers to monitor heart health remotely. Keystone Heart primarily serves hospitals, outpatient clinics, and healthcare professionals, marketing its products across North America and Europe to cardiologists and general practitioners who rely on these technologies to improve patient care.Revenue generation at Keystone Heart is primarily driven by the direct sales of its heart monitoring systems to healthcare institutions, along with subscription-based services for ongoing monitoring and data analysis. Transactions involve B2B contracts where hospitals procure units in bulk for their cardiology departments. Additionally, the company offers maintenance and support plans, establishing a recurring revenue stream. Pricing varies based on device volume and service levels, including enhanced analytics and reporting options integrated with their flagship products to promote comprehensive patient care and foster long-term client relationships.Keystone Heart Ltd. aims to expand its market presence by introducing new products designed for cardiovascular monitoring, with specific release dates to be determined. The company is targeting expansion into new geographic regions, particularly aiming to penetrate additional markets in Europe and North America by 2025. The recent funding of USD 14.00 mn, secured through a Series B round, will be utilized to support these initiatives and enhance its product development capabilities. The acquisition by Venus MedTech positions Keystone Heart strategically to leverage additional resources and expertise for future growth.

## Funding rounds

- Series B, May 15, 2014, $14M — OrbiMed Advisors, Caesarea Medical Electronics Ltd.

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Caesarea Medical Electronics Ltd. — Series B